Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Stem cell vesicles reduced eczema symptoms in mice safely.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Candida antigen is an effective and promising treatment for alopecia areata.

Belatacept may be a promising treatment for alopecia areata.

Baricitinib works better than methotrexate for severe alopecia areata.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Stem Cell Educator therapy helps regrow hair and improve life quality in alopecia areata patients.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.

Tofacitinib can help regrow hair in about 50% of people with moderate-severe alopecia areata.

The FDA rejected a testosterone drug again due to safety concerns.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Bimekizumab can improve scarring alopecia in severe psoriasis.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.